H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and ...

Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

CorMedix, a biopharmaceutical company specialising in critical care products, is to acquire Melinta Therapeutics for $300m.

The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

The US FDA has given accelerated approval to Jazz Pharma for Modeyso to treat adult and paediatric patients with diffuse midline glioma.

The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market.

The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.